Streamlining Rheumatology Fax & Paper Form Automation

Klivira specializes in optimizing rheumatology fax & paper form automation, transforming manual PA processes into efficient, digital workflows for high-cost biologics and infusions.

Revenue cycle leaders and PA coordinators in rheumatology face significant administrative overhead due to the persistent reliance on fax and paper forms by numerous payers for prior authorizations. This challenge is particularly acute for chronic biologic therapies, where re-authorizations and complex documentation requirements often necessitate manual form completion and submission. Klivira’s platform digitizes these long-tail payer fax workflows, reducing delays and staff burden.

The Persistent Challenge of Fax and Paper in Rheumatology PA

Rheumatology prior authorizations are heavily concentrated in high-cost biologic and targeted therapies, including TNF-alpha inhibitors (e.g., Humira, Enbrel), non-TNF biologics, JAK inhibitors, and infusion therapy. Despite advancements in digital channels, many payers continue to mandate fax or paper submissions for these critical medications, creating significant bottlenecks. The chronic nature of rheumatic diseases often necessitates periodic re-authorization, compounding the manual burden of these long-tail payer fax workflows.

Key Rheumatology PA Categories Requiring Fax Automation

TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab)
Non-TNF biologics and targeted synthetic DMARDs (e.g., IL-6, IL-17, IL-23 inhibitors, JAK inhibitors)
Specialty drugs for specific indications (e.g., anifrolumab for SLE, belimumab for SLE)
Advanced imaging for inflammatory arthritis assessment
DEXA scans for osteoporosis management in chronic-steroid patients

Klivira's Approach to Rheumatology Fax & Paper Form Automation

Klivira leverages advanced Optical Character Recognition (OCR) and intelligent form-filling capabilities to automate the conversion of complex, payer-specific fax and PDF forms into structured data. For rheumatology, this means that detailed clinical information required for biologics and infusion therapies can be extracted from the EMR and accurately populated onto the correct forms, even when X12 278 or ePA channels are unavailable. This significantly reduces manual data entry and transcription errors.

Critical Documentation for Rheumatology PAs on Fax Forms

Diagnosis documentation: ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA)
Disease activity assessment: Scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE
Prior conventional DMARD trial: Documentation of methotrexate, sulfasalazine, or other csDMARD trial and response
Step therapy compliance: Proof of failure for required TNF inhibitors or biosimilar substitution attempts
Screening completion: TB screening (PPD or IGRA), hepatitis B/C screening, and immunization status for immunosuppressive biologics

Streamlining Complex Rheumatology Workflows

Rheumatology presents unique workflow constraints, including chronic-treatment ongoing PA burden, variable biosimilar substitution policies, and complex step therapy rules that interact with brand-vs-biosimilar mandates. Klivira's platform is designed to manage these nuances by applying ACR-guideline-aware policy logic for step therapy sequencing and biosimilar routing. This ensures that even when submitting via fax, the documentation reflects the specific requirements for medical vs. pharmacy benefit split and pediatric-specific PA flows, minimizing common denial reasons like 'step therapy not completed' or 'biosimilar substitution required'.

Seamless EMR Integration for Rheumatology Workflows

Klivira integrates directly with your EMR system, leveraging standards like SMART on FHIR, to pull the comprehensive clinical data needed for rheumatology prior authorizations. This includes diagnosis, disease activity scores, prior treatment history, and screening results. By automating the data flow from the EMR to payer fax forms, Klivira eliminates manual data entry, reduces the risk of errors, and accelerates the entire prior authorization process for biologics and infusion therapies.

Frequently asked questions

How does Klivira handle payer-specific fax forms for rheumatology biologics?

Klivira uses advanced OCR and intelligent form-filling to accurately extract and populate data from EMRs onto specific payer fax forms. This ensures correct submission even for long-tail payers that lack digital submission channels, significantly reducing manual effort for high-volume rheumatology medications.

Can Klivira automate re-authorizations for chronic rheumatology treatments?

Yes, Klivira's platform supports periodic re-authorization workflows common in rheumatology. It tracks re-auth schedules and helps automate the generation and submission of required documentation, including continuous disease response data, for ongoing biologic therapies.

How does Klivira address step therapy and biosimilar requirements in faxed PAs?

Klivira's policy logic incorporates ACR-guideline-aware step therapy sequencing and biosimilar substitution mandates specific to each payer. For faxed submissions, it ensures that the required prior agent trials and biosimilar considerations are accurately documented on the forms before submission.

What EMR data does Klivira use for rheumatology fax automation?

Klivira integrates with EMRs to pull relevant clinical data, including diagnosis documentation (ICD-10, ACR/EULAR criteria), disease activity assessments (DAS28, CDAI), prior DMARD trial history, and screening results (TB, hepatitis B/C). This data is then used to pre-populate payer fax forms.

Is Klivira compliant with HIPAA for handling PHI in fax automation?

Klivira operates with robust security protocols designed to protect PHI and ePHI, aligning with HIPAA requirements. Our platform ensures that patient data handled during the fax automation process is secured throughout its lifecycle, from EMR extraction to payer submission.